BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors. 2008

Brian L Robbins, and Edmund V Capparelli, and Ellen G Chadwick, and Ram Yogev, and Leslie Serchuck, and Carol Worrell, and Mary Elizabeth Smith, and Carmelita Alvero, and Terence Fenton, and Barbara Heckman, and Stephen I Pelton, and Grace Aldrovandi, and William Borkowsky, and John Rodman, and Peter L Havens, and
St Jude Children's Research Hospital, Memphis, Tennessee, USA.

Human immunodeficiency virus (HIV)-infected children and adolescents who are failing antiretrovirals may have a better virologic response when drug exposures are increased, using higher protease inhibitor doses or ritonavir boosting. We studied the pharmacokinetics and safety of high-dose lopinavir-ritonavir (LPV/r) in treatment-experienced patients, using an LPV/r dose of 400/100 mg/m(2) orally every 12 h (p.o. q12h) (without nonnucleoside reverse transcriptase inhibitor [NNRTI]), or 480/120 mg/m(2) p.o. q12h (with NNRTI). We calculated the LPV inhibitory quotient (IQ), and when the IQ was <15, saquinavir (SQV) 750 mg/m(2) p.o. q12h was added to the regimen. We studied 26 HIV-infected patients. The median age was 15 years (range, 7 to 17), with 11.5 prior antiretroviral medications, 197 CD4 cells/ml, viral load of 75,577 copies/ml, and a 133-fold change in LPV resistance. By treatment week 2, 14 patients had a viral-load decrease of >0.75 log(10), with a median maximal decrease in viral load of -1.57 log(10) copies/ml at week 8. At week 2, 19 subjects showed a median LPV area under the concentration-time curve (AUC) of 157.2 (range, 62.8 to 305.5) microg x h/ml and median LPV trough concentration (C(trough)) of 10.8 (range, 4.1 to 25.3) microg/ml. In 16 subjects with SQV added, the SQV median AUC was 33.7 (range, 4.4 to 76.5) microg x h/ml and the median SQV C(trough) was 2.1 (range, 0.2 to 4.1) microg/ml. At week 24, 18 of 26 (69%) subjects remained in the study. Between weeks 24 and 48, one subject withdrew for nonadherence and nine withdrew for persistently high virus load. In antiretroviral-experienced children and adolescents with HIV, high doses of LPV/r with or without SQV offer safe options for salvage therapy, but the modest virologic response and the challenge of adherence to a regimen with a high pill burden may limit the usefulness of this approach.

UI MeSH Term Description Entries
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D061466 Lopinavir An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A. A-157378.0,ABT 378,ABT-378,N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide,A 157378.0,A157378.0,ABT378
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse

Related Publications

Brian L Robbins, and Edmund V Capparelli, and Ellen G Chadwick, and Ram Yogev, and Leslie Serchuck, and Carol Worrell, and Mary Elizabeth Smith, and Carmelita Alvero, and Terence Fenton, and Barbara Heckman, and Stephen I Pelton, and Grace Aldrovandi, and William Borkowsky, and John Rodman, and Peter L Havens, and
Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
July 2010, Antimicrobial agents and chemotherapy,
Brian L Robbins, and Edmund V Capparelli, and Ellen G Chadwick, and Ram Yogev, and Leslie Serchuck, and Carol Worrell, and Mary Elizabeth Smith, and Carmelita Alvero, and Terence Fenton, and Barbara Heckman, and Stephen I Pelton, and Grace Aldrovandi, and William Borkowsky, and John Rodman, and Peter L Havens, and
Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
November 2007, HIV medicine,
Brian L Robbins, and Edmund V Capparelli, and Ellen G Chadwick, and Ram Yogev, and Leslie Serchuck, and Carol Worrell, and Mary Elizabeth Smith, and Carmelita Alvero, and Terence Fenton, and Barbara Heckman, and Stephen I Pelton, and Grace Aldrovandi, and William Borkowsky, and John Rodman, and Peter L Havens, and
Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women.
February 2004, Antimicrobial agents and chemotherapy,
Brian L Robbins, and Edmund V Capparelli, and Ellen G Chadwick, and Ram Yogev, and Leslie Serchuck, and Carol Worrell, and Mary Elizabeth Smith, and Carmelita Alvero, and Terence Fenton, and Barbara Heckman, and Stephen I Pelton, and Grace Aldrovandi, and William Borkowsky, and John Rodman, and Peter L Havens, and
Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors.
June 2002, Antimicrobial agents and chemotherapy,
Brian L Robbins, and Edmund V Capparelli, and Ellen G Chadwick, and Ram Yogev, and Leslie Serchuck, and Carol Worrell, and Mary Elizabeth Smith, and Carmelita Alvero, and Terence Fenton, and Barbara Heckman, and Stephen I Pelton, and Grace Aldrovandi, and William Borkowsky, and John Rodman, and Peter L Havens, and
Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.
February 2009, The Pediatric infectious disease journal,
Brian L Robbins, and Edmund V Capparelli, and Ellen G Chadwick, and Ram Yogev, and Leslie Serchuck, and Carol Worrell, and Mary Elizabeth Smith, and Carmelita Alvero, and Terence Fenton, and Barbara Heckman, and Stephen I Pelton, and Grace Aldrovandi, and William Borkowsky, and John Rodman, and Peter L Havens, and
Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
December 2001, Antimicrobial agents and chemotherapy,
Brian L Robbins, and Edmund V Capparelli, and Ellen G Chadwick, and Ram Yogev, and Leslie Serchuck, and Carol Worrell, and Mary Elizabeth Smith, and Carmelita Alvero, and Terence Fenton, and Barbara Heckman, and Stephen I Pelton, and Grace Aldrovandi, and William Borkowsky, and John Rodman, and Peter L Havens, and
Analysis of env sequence evolution in human immunodeficiency virus-infected patients receiving therapy with nonnucleoside reverse-transcriptase inhibitors.
July 2000, The Journal of infectious diseases,
Brian L Robbins, and Edmund V Capparelli, and Ellen G Chadwick, and Ram Yogev, and Leslie Serchuck, and Carol Worrell, and Mary Elizabeth Smith, and Carmelita Alvero, and Terence Fenton, and Barbara Heckman, and Stephen I Pelton, and Grace Aldrovandi, and William Borkowsky, and John Rodman, and Peter L Havens, and
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.
January 2003, Antimicrobial agents and chemotherapy,
Brian L Robbins, and Edmund V Capparelli, and Ellen G Chadwick, and Ram Yogev, and Leslie Serchuck, and Carol Worrell, and Mary Elizabeth Smith, and Carmelita Alvero, and Terence Fenton, and Barbara Heckman, and Stephen I Pelton, and Grace Aldrovandi, and William Borkowsky, and John Rodman, and Peter L Havens, and
Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.
April 1998, Clinical pharmacology and therapeutics,
Brian L Robbins, and Edmund V Capparelli, and Ellen G Chadwick, and Ram Yogev, and Leslie Serchuck, and Carol Worrell, and Mary Elizabeth Smith, and Carmelita Alvero, and Terence Fenton, and Barbara Heckman, and Stephen I Pelton, and Grace Aldrovandi, and William Borkowsky, and John Rodman, and Peter L Havens, and
Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
December 2002, AIDS research and human retroviruses,
Copied contents to your clipboard!